Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer

Seminars in Oncology

Volumn 30, Issue 2 SUPPL. 3, 2003, Pages 19-21

  Sledge Jr, George W ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GENE OVEREXPRESSION; GRANULOCYTOPENIA; HUMAN; INFECTION; INTERMETHOD COMPARISON; LEUKOPENIA; LIVER TOXICITY; METASTASIS; MYALGIA; NAUSEA; NEUROPATHY; NEUROSENSORY TOXICITY; NEUTROPENIA; ONCOGENE NEU; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; VOMITING;

EID: 0037398911     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2003.37271     Document Type: Conference Paper

References (13)

1. Carmichael J, Possinger K, Phillip P, et al: Advanced breast cancer: A phase II trial with gemcitabine. J Clin Oncol 13:2731-2736, 1995
2. Possinger K, Kaufmann M, Coleman R, et al: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10: 155-162, 1999
3. Spielmann M, Llombart-Cussac A, Kalla S, et al. Singleagent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60:303-307, 2001
4. Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial. Oncology 62:2-8, 2002
5. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
6. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
7. Holmes FA, Valero V, Walters RS, et al: The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 1993 15:161-169, 1993
8. Einhorn L, Raghavan D, Kindler H, et al: A phase I trial of gemcitabine plus paclitaxel combination therapy in patients with refractory solid tumors. Proc Am Soc Clin Oncol 17:796a, 1998 (abstr)
9. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98A, 1998 (abstr)
10. Sanchez-Rovira P, Medina MB, Mohendano N, et al: Results from a phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Ann Oncol 9:A77P, 1998 (suppl 4) (abstr)
11. Colomer R, Llombart A, Lluch A, et al: Biweekly paclitaxel and gemcitabine in advanced breast cancer. Phase II trial and predictive value of Her2 extracellular domain (ECD). Proc Am Soc Clin Oncol 19:A373, 2000 (abstr)
12. Murad AM, Guimaraes RC, Aragao BC, et al: Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer. Am J Clin Oncol 24:264-269, 2001.
13. Miller KD, Sisk J, Ansari R, et al: Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology (Huntingt) 15:38-40, 2001 (suppl 3)